ArticleClinical and translational science2024

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Debbie Robbrecht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.